Archives of Gynecology and Obstetrics

, Volume 287, Issue 6, pp 1187–1204

Ovarian epithelial tumors and reproductive factors: a systematic review

  • Susanne Schüler
  • Marvin Ponnath
  • Jörg Engel
  • Olaf Ortmann
Gynecologic Oncology

Abstract

Purpose

The aim of this systematic review is to summarize the current knowledge about the etiology and pathogenesis of borderline tumors ovarian cancer with special emphasis on the role of endocrine treatments and reproductive factors to establish a foundation for future studies.

Methods

We performed a systematic review on the relation between ovarian epithelial tumors (OET) and reproductive factors using the keywords: ovarian cancer, ovarian tumor, ovarian borderline tumor, age at menarche, age at menopause, parity, infertility, PCO syndrome, oral contraception, menopausal hormone therapy, fertility treatment. Totally, 3,290 abstracts were scanned for their relevance in this publication and 127 were finally included.

Results

The incidence of ovarian epithelial cancer and ovarian borderline tumors is influenced by certain reproductive factors. The strongest protective effects are conferred by parity and use of oral contraceptive pills. Recent molecular biologic and histopathologic studies prove that OET represent a diverse group of tumors, each histologic type with a different genetic background. This is at least partly reflected in epidemiologic and clinical studies showing different risk modulating effects of reproductive factors and endocrine therapies on OET.

Conclusions

The etiology and pathogenesis of ovarian cancer are still not fully understood. None of the so far proposed hypothesis on the development of OET can fully account for the epidemiologic and clinical findings in the context of reproductive factors and OET development. Further research approaches are warranted and need to put more weight on the clinical and genetical diversity of OET to yield a more detailed insight into their pathogenesis.

Keywords

Epithelial ovarian tumors Ovarian cancer Borderline ovarian tumors Reproductive factors Endocrine factors Age at menarche Age at menopause Parity Infertility PCO syndrome Oral contraception Menopausal hormone therapy Fertility treatment 

References

  1. 1.
    Siegel R, Naishadham D, Jemal A (2012) Cancer statistics. CA Cancer J Clin 62(1):10–29. doi:10.3322/caac.20138 PubMedCrossRefGoogle Scholar
  2. 2.
    Gershenson DM (2002) Clinical management potential tumours of low malignancy. Best Pract Res Clin Obstet Gynaecol 16(4):513–527. pii: S1521693402903081PubMedCrossRefGoogle Scholar
  3. 3.
    Bonome T, Lee JY, Park DC, Radonovich M, Pise-Masison C, Brady J, Gardner GJ, Hao K, Wong WH, Barrett JC, Lu KH, Sood AK, Gershenson DM, Mok SC, Birrer MJ (2005) Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 65(22):10602–10612. doi:10.1158/0008-5472.CAN-05-2240 PubMedCrossRefGoogle Scholar
  4. 4.
    Tsai HW, Ko CC, Yeh CC, Chen YJ, Twu NF, Chao KC, Yen MS (2011) Unilateral salpingo-oophorectomy as fertility-sparing surgery for borderline ovarian tumors. J Chin Med Assoc 74(6):250–254. doi:10.1016/j.jcma.2011.04.003 PubMedCrossRefGoogle Scholar
  5. 5.
    Sherman ME, Mink PJ, Curtis R, Cote TR, Brooks S, Hartge P, Devesa S (2004) Survival among women with borderline ovarian tumors and ovarian carcinoma: a population-based analysis. Cancer 100(5):1045–1052. doi:10.1002/cncr.20080 PubMedCrossRefGoogle Scholar
  6. 6.
    Kurman RJ, Shih Ie M (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer–shifting the paradigm. Hum Pathol 42(7):918–931. doi:10.1016/j.humpath.2011.03.003 PubMedCrossRefGoogle Scholar
  7. 7.
    Burks RT, Sherman ME, Kurman RJ (1996) Micropapillary serous carcinoma of the ovary. A distinctive low-grade carcinoma related to serous borderline tumors. Am J Surg Pathol 20(11):1319–1330PubMedCrossRefGoogle Scholar
  8. 8.
    Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG (2004) Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 28(4):496–504. pii: 00000478-200404000-00009PubMedCrossRefGoogle Scholar
  9. 9.
    Bell DA, Longacre TA, Prat J, Kohn EC, Soslow RA, Ellenson LH, Malpica A, Stoler MH, Kurman RJ (2004) Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives. Hum Pathol 35(8):934–948. pii: S0046817704001546PubMedCrossRefGoogle Scholar
  10. 10.
    Gershenson DM, Silva EG, Tortolero-Luna G, Levenback C, Morris M, Tornos C (1998) Serous borderline tumors of the ovary with noninvasive peritoneal implants. Cancer 83(10):2157–2163. doi:10.1002/(SICI)1097-0142(19981115)83:10<2157:AID-CNCR14>3.0.CO;2-D PubMedCrossRefGoogle Scholar
  11. 11.
    Singer G, Kurman RJ, Chang HW, Cho SK, Shih Ie M (2002) Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol 160(4):1223–1228. pii: S0002-9440(10)62549-7PubMedCrossRefGoogle Scholar
  12. 12.
    Singer G, Oldt R 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih Ie M (2003) Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 95(6):484–486PubMedCrossRefGoogle Scholar
  13. 13.
    Ho CL, Kurman RJ, Dehari R, Wang TL, Shih Ie M (2004) Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Cancer Res 64(19):6915–6918. doi:10.1158/0008-5472.CAN-04-2067 PubMedCrossRefGoogle Scholar
  14. 14.
    Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R, Waddell N, Simms L, Locandro B, Fereday S, Traficante N, Russell P, Sharma R, Birrer MJ, deFazio A, Chenevix-Trench G, Bowtell DD (2008) Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 6(11):1678–1690. doi:10.1158/1541-7786.MCR-08-0193 PubMedCrossRefGoogle Scholar
  15. 15.
    Integrated genomic analyses of ovarian carcinoma (2011). Nature 474 (7353):609-615. doi:10.1038/nature10166
  16. 16.
    Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, Stewart C, Fereday S, Caldas C, Defazio A, Bowtell D, Brenton JD (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221(1):49–56. doi:10.1002/path.2696 PubMedCrossRefGoogle Scholar
  17. 17.
    Chen HH, Wang YC, Fann MJ (2006) Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation. Mol Cell Biol 26(7):2736–2745. doi:10.1128/MCB.26.7.2736-2745.2006 PubMedCrossRefGoogle Scholar
  18. 18.
    Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan MB, Fulton L, Fulton RS, Zhang Q, Wendl MC, Lawrence MS, Larson DE, Chen K, Dooling DJ, Sabo A, Hawes AC, Shen H, Jhangiani SN, Lewis LR, Hall O, Zhu Y, Mathew T, Ren Y, Yao J, Scherer SE, Clerc K, Metcalf GA, Ng B, Milosavljevic A, Gonzalez-Garay ML, Osborne JR, Meyer R, Shi X, Tang Y, Koboldt DC, Lin L, Abbott R, Miner TL, Pohl C, Fewell G, Haipek C, Schmidt H, Dunford-Shore BH, Kraja A, Crosby SD, Sawyer CS, Vickery T, Sander S, Robinson J, Winckler W, Baldwin J, Chirieac LR, Dutt A, Fennell T, Hanna M, Johnson BE, Onofrio RC, Thomas RK, Tonon G, Weir BA, Zhao X, Ziaugra L, Zody MC, Giordano T, Orringer MB, Roth JA, Spitz MR, Wistuba II, Ozenberger B, Good PJ, Chang AC, Beer DG, Watson MA, Ladanyi M, Broderick S, Yoshizawa A, Travis WD, Pao W, Province MA, Weinstock GM, Varmus HE, Gabriel SB, Lander ES, Gibbs RA, Meyerson M, Wilson RK (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216):1069–1075. doi:10.1038/nature07423 PubMedCrossRefGoogle Scholar
  19. 19.
    Aldred MA, Trembath RC (2000) Activating and inactivating mutations in the human GNAS1 gene. Hum Mutat 16(3):183–189. doi:10.1002/1098-1004(200009)16:3<183:AID-HUMU1>3.0.CO;2-L PubMedCrossRefGoogle Scholar
  20. 20.
    Kelemen LE, Kobel M (2011) Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol 12(11):1071–1080. doi:10.1016/S1470-2045(11)70058-4 PubMedCrossRefGoogle Scholar
  21. 21.
    Hart WR (2005) Mucinous tumors of the ovary: a review. Int J Gynecol Pathol 24(1):4–25. pii: 00004347-200501000-00003PubMedGoogle Scholar
  22. 22.
    Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM (1991) K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139(4):777–785PubMedGoogle Scholar
  23. 23.
    Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, Venkatraman E, Boyd J (2003) Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 90(2):378–381. pii: S0090825803002646PubMedCrossRefGoogle Scholar
  24. 24.
    Mayr D, Hirschmann A, Lohrs U, Diebold J (2006) KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 103(3):883–887. doi:10.1016/j.ygyno.2006.05.029 PubMedCrossRefGoogle Scholar
  25. 25.
    Mok SC, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, Berkowitz RS, Tsao SW (1993) Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 53(7):1489–1492PubMedGoogle Scholar
  26. 26.
    Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih Ie M (2008) Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 198(4):351–356. doi:10.1016/j.ajog.2008.01.005 PubMedCrossRefGoogle Scholar
  27. 27.
    Landen CN Jr, Birrer MJ, Sood AK (2008) Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 26(6):995–1005. doi:10.1200/JCO.2006.07.9970 PubMedCrossRefGoogle Scholar
  28. 28.
    Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih Ie M (2009) Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 174(5):1597–1601. doi:10.2353/ajpath.2009.081000 PubMedCrossRefGoogle Scholar
  29. 29.
    Yamamoto S, Tsuda H, Takano M, Iwaya K, Tamai S, Matsubara O (2011) PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. J Pathol 225(2):189–194. doi:10.1002/path.2940 PubMedCrossRefGoogle Scholar
  30. 30.
    Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O (2011) Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol. doi:10.1038/modpathol.2011.189 Google Scholar
  31. 31.
    Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O (2011) Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. Mod Pathol 24(8):1146–1155. doi:10.1038/modpathol.2011.70 PubMedCrossRefGoogle Scholar
  32. 32.
    Kuo KT, Mao TL, Chen X, Feng Y, Nakayama K, Wang Y, Glas R, Ma MJ, Kurman RJ, Shih Ie M, Wang TL (2010) DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res 16(7):1997–2008. doi:10.1158/1078-0432.CCR-09-2105 PubMedCrossRefGoogle Scholar
  33. 33.
    Wu R, Zhai Y, Fearon ER, Cho KR (2001) Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res 61(22):8247–8255PubMedGoogle Scholar
  34. 34.
    Moreno-Bueno G, Gamallo C, Perez-Gallego L, de Mora JC, Suarez A, Palacios J (2001) Beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 10(2):116–122PubMedCrossRefGoogle Scholar
  35. 35.
    Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, Senz J, McConechy MK, Anglesio MS, Kalloger SE, Yang W, Heravi-Moussavi A, Giuliany R, Chow C, Fee J, Zayed A, Prentice L, Melnyk N, Turashvili G, Delaney AD, Madore J, Yip S, McPherson AW, Ha G, Bell L, Fereday S, Tam A, Galletta L, Tonin PN, Provencher D, Miller D, Jones SJ, Moore RA, Morin GB, Oloumi A, Boyd N, Aparicio SA, Shih Ie M, Mes-Masson AM, Bowtell DD, Hirst M, Gilks B, Marra MA, Huntsman DG (2010) ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363(16):1532–1543. doi:10.1056/NEJMoa1008433 PubMedCrossRefGoogle Scholar
  36. 36.
    Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, Campbell IG (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58(10):2095–2097PubMedGoogle Scholar
  37. 37.
    Saito M, Okamoto A, Kohno T, Takakura S, Shinozaki H, Isonishi S, Yasuhara T, Yoshimura T, Ohtake Y, Ochiai K, Yokota J, Tanaka T (2000) Allelic imbalance and mutations of the PTEN gene in ovarian cancer. Int J Cancer 85(2):160–165. doi:10.1002/(SICI)1097-0215(20000115)85:2<160:AID-IJC2>3.0.CO;2-5 PubMedGoogle Scholar
  38. 38.
    Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, Noguchi M (2000) Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 60(24):7052–7056PubMedGoogle Scholar
  39. 39.
    Prowse AH, Manek S, Varma R, Liu J, Godwin AK, Maher ER, Tomlinson IP, Kennedy SH (2006) Molecular genetic evidence that endometriosis is a precursor of ovarian cancer. Int J Cancer 119(3):556–562. doi:10.1002/ijc.21845 PubMedCrossRefGoogle Scholar
  40. 40.
    Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T (2005) Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 11(1):63–70. doi:10.1038/nm1173 PubMedCrossRefGoogle Scholar
  41. 41.
    Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, Hanash S, Misek DE, Katabuchi H, Williams BO, Fearon ER, Cho KR (2007) Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3 K/Pten signaling pathways. Cancer Cell 11(4):321–333. doi:10.1016/j.ccr.2007.02.016 PubMedCrossRefGoogle Scholar
  42. 42.
    Kang SK, Choi KC, Cheng KW, Nathwani PS, Auersperg N, Leung PC (2000) Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium. Endocrinology 141(1):72–80PubMedCrossRefGoogle Scholar
  43. 43.
    Emons G, Pahwa GS, Brack C, Sturm R, Oberheuser F, Knuppen R (1989) Gonadotropin releasing hormone binding sites in human epithelial ovarian carcinomata. Eur J Cancer Clin Oncol 25(2):215–221PubMedCrossRefGoogle Scholar
  44. 44.
    Emons G, Ortmann O, Pahwa GS, Hackenberg R, Oberheuser F, Schulz KD (1992) Intracellular actions of gonadotropic and peptide hormones and the therapeutic value of GnRH-agonists in ovarian cancer. Acta Obstet Gynecol Scand Suppl 155:31–38PubMedGoogle Scholar
  45. 45.
    Irmer G, Burger C, Muller R, Ortmann O, Peter U, Kakar SS, Neill JD, Schulz KD, Emons G (1995) Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 55(4):817–822PubMedGoogle Scholar
  46. 46.
    So WK, Cheng JC, Poon SL, Leung PC (2008) Gonadotropin-releasing hormone and ovarian cancer: a functional and mechanistic overview. FEBS J 275(22):5496–5511. doi:10.1111/j.1742-4658.2008.06679.x PubMedCrossRefGoogle Scholar
  47. 47.
    Emons G, Ortmann O, Becker M, Irmer G, Springer B, Laun R, Holzel F, Schulz KD, Schally AV (1993) High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53(22):5439–5446PubMedGoogle Scholar
  48. 48.
    Emons G, Pahwa GS, Ortmann O, Knuppen R, Oberheuser F, Schulz KD (1990) LHRH-receptors and LHRH-agonist treatment in ovarian cancer: an overview. J Steroid Biochem Mol Biol 37(6):1003–1006. pii: 0960-0760(90)90457-VPubMedCrossRefGoogle Scholar
  49. 49.
    Emons G, Weiss S, Ortmann O, Grundker C, Schulz KD (2000) LHRH might act as a negative autocrine regulator of proliferation of human ovarian cancer. Eur J Endocrinol 142(6):665–670. doi:10.1530/eje.0.1420665 PubMedCrossRefGoogle Scholar
  50. 50.
    Ling Poon S, Lau MT, Hammond GL, Leung PC (2011) Gonadotropin-releasing hormone-II increases membrane type I metalloproteinase production via beta-catenin signaling in ovarian cancer cells. Endocrinology 152(3):764–772. doi:10.1210/en.2010-0942 PubMedCrossRefGoogle Scholar
  51. 51.
    Zheng W, Magid MS, Kramer EE, Chen YT (1996) Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am J Pathol 148(1):47–53PubMedGoogle Scholar
  52. 52.
    Bose CK (2008) Follicle stimulating hormone receptor in ovarian surface epithelium and epithelial ovarian cancer. Oncol Res 17(5):231–238PubMedCrossRefGoogle Scholar
  53. 53.
    Parrott JA, Doraiswamy V, Kim G, Mosher R, Skinner MK (2001) Expression and actions of both the follicle stimulating hormone receptor and the luteinizing hormone receptor in normal ovarian surface epithelium and ovarian cancer. Mol Cell Endocrinol 172(1–2):213–222. pii: S0303-7207(00)00340-3PubMedCrossRefGoogle Scholar
  54. 54.
    Lu JJ, Zheng Y, Kang X, Yuan JM, Lauchlan SC, Pike MC, Zheng W (2000) Decreased luteinizing hormone receptor mRNA expression in human ovarian epithelial cancer. Gynecol Oncol 79(2):158–168. doi:10.1006/gyno.2000.5928 PubMedCrossRefGoogle Scholar
  55. 55.
    Chudecka-Glaz A, Rzepka-Gorska I, Kosmowska B (2004) Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary. Arch Gynecol Obstet 270(3):151–156. doi:10.1007/s00404-003-0519-4 PubMedCrossRefGoogle Scholar
  56. 56.
    Mandai M, Konishi I, Kuroda H, Fukumoto M, Komatsu T, Yamamoto S, Nanbu K, Rao CV, Mori T (1997) Messenger ribonucleic acid expression of LH/hCG receptor gene in human ovarian carcinomas. Eur J Cancer 33(9):1501–1507. pii: S0959804997001664PubMedCrossRefGoogle Scholar
  57. 57.
    Tourgeman DE, Lu JJ, Boostanfar R, Amezcua C, Felix JC, Paulson RJ (2002) Human chorionic gonadotropin suppresses ovarian epithelial neoplastic cell proliferation in vitro. Fertil Steril 78(5):1096–1099. pii: S0015028202033678PubMedCrossRefGoogle Scholar
  58. 58.
    Choi JH, Choi KC, Auersperg N, Leung PC (2004) Overexpression of follicle-stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 89(11):5508–5516. doi:10.1210/jc.2004-0044 PubMedCrossRefGoogle Scholar
  59. 59.
    Tashiro H, Katabuchi H, Begum M, Li X, Nitta M, Ohtake H, Okamura H (2003) Roles of luteinizing hormone/chorionic gonadotropin receptor in anchorage-dependent and -independent growth in human ovarian surface epithelial cell lines. Cancer Sci 94(11):953–959PubMedCrossRefGoogle Scholar
  60. 60.
    Ji Q, Liu PI, Chen PK, Aoyama C (2004) Follicle stimulating hormone-induced growth promotion and gene expression profiles on ovarian surface epithelial cells. Int J Cancer 112(5):803–814. doi:10.1002/ijc.20478 PubMedCrossRefGoogle Scholar
  61. 61.
    Lau MT, Wong AS, Leung PC (2010) Gonadotropins induce tumor cell migration and invasion by increasing cyclooxygenases expression and prostaglandin E(2) production in human ovarian cancer cells. Endocrinology 151(7):2985–2993. doi:10.1210/en.2009-1318 PubMedCrossRefGoogle Scholar
  62. 62.
    Schiffenbauer YS, Meir G, Maoz M, Even-Ram SC, Bar-Shavit R, Neeman M (2002) Gonadotropin stimulation of MLS human epithelial ovarian carcinoma cells augments cell adhesion mediated by CD44 and by alpha(v)-integrin. Gynecol Oncol 84(2):296–302. doi:10.1006/gyno.2001.6512 PubMedCrossRefGoogle Scholar
  63. 63.
    Zygmunt M, Herr F, Keller-Schoenwetter S, Kunzi-Rapp K, Munstedt K, Rao CV, Lang U, Preissner KT (2002) Characterization of human chorionic gonadotropin as a novel angiogenic factor. J Clin Endocrinol Metab 87(11):5290–5296PubMedCrossRefGoogle Scholar
  64. 64.
    Wang J, Luo F, Lu JJ, Chen PK, Liu P, Zheng W (2002) VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int J Cancer 97(2):163–167. doi:10.1002/ijc.1593 PubMedCrossRefGoogle Scholar
  65. 65.
    Basille C, Olivennes F, Le Calvez J, Beron-Gaillard N, Meduri G, Lhomme C, Duvillard P, Benard J, Morice P (2006) Impact of gonadotrophins and steroid hormones on tumour cells derived from borderline ovarian tumours. Hum Reprod 21(12):3241–3245. doi:10.1093/humrep/del301 PubMedCrossRefGoogle Scholar
  66. 66.
    Heinonen PK, Koivula T, Rajaniemi H, Pystynen P (1986) Peripheral and ovarian venous concentrations of steroid and gonadotropin hormones in postmenopausal women with epithelial ovarian tumors. Gynecol Oncol 25(1):1–10PubMedCrossRefGoogle Scholar
  67. 67.
    Cunat S, Rabenoelina F, Daures JP, Katsaros D, Sasano H, Miller WR, Maudelonde T, Pujol P (2005) Aromatase expression in ovarian epithelial cancers. J Steroid Biochem Mol Biol 93(1):15–24. doi:10.1016/j.jsbmb.2004.10.021 PubMedCrossRefGoogle Scholar
  68. 68.
    Brandenberger AW, Tee MK, Jaffe RB (1998) Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab 83(3):1025–1028PubMedCrossRefGoogle Scholar
  69. 69.
    Galtier-Dereure F, Capony F, Maudelonde T, Rochefort H (1992) Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1. J Clin Endocrinol Metab 75(6):1497–1502PubMedCrossRefGoogle Scholar
  70. 70.
    Song J, Fadiel A, Edusa V, Chen Z, So J, Sakamoto H, Fishman DA, Naftolin F (2005) Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett 220(1):57–65. doi:10.1016/j.canlet.2004.04.024 PubMedCrossRefGoogle Scholar
  71. 71.
    Keith Bechtel M, Bonavida B (2001) Inhibitory effects of 17beta-estradiol and progesterone on ovarian carcinoma cell proliferation: a potential role for inducible nitric oxide synthase. Gynecol Oncol 82(1):127–138. doi:10.1006/gyno.2001.6221 PubMedCrossRefGoogle Scholar
  72. 72.
    Bai W, Oliveros-Saunders B, Wang Q, Acevedo-Duncan ME, Nicosia SV (2000) Estrogen stimulation of ovarian surface epithelial cell proliferation. In Vitro Cell Dev Biol Anim 36(10):657–666. doi:10.1290/1071-2690(2000)036<0657:ESOOSE>2.0.CO;2 PubMedCrossRefGoogle Scholar
  73. 73.
    Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM (2001) Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 61(18):6768–6776PubMedGoogle Scholar
  74. 74.
    Bardin A, Moll F, Margueron R, Delfour C, Chu ML, Maudelonde T, Cavailles V, Pujol P (2005) Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells. Endocrinology 146(2):760–768. doi:10.1210/en.2004-1239 PubMedCrossRefGoogle Scholar
  75. 75.
    Yousef GM, Diamandis EP (2002) Kallikreins, steroid hormones and ovarian cancer: is there a link? Minerva Endocrinol 27(3):157–166PubMedGoogle Scholar
  76. 76.
    Simpson BJ, Langdon SP, Rabiasz GJ, Macleod KG, Hirst GL, Bartlett JM, Crew AJ, Hawkins RA, Macineira-Perez PP, Smyth JF, Miller WR (1998) Estrogen regulation of transforming growth factor-alpha in ovarian cancer. J Steroid Biochem Mol Biol 64(3–4):137–145. pii: S0960-0760(97)00159-3PubMedCrossRefGoogle Scholar
  77. 77.
    Wimalasena J, Meehan D, Dostal R, Foster JS, Cameron M, Smith M (1993) Growth factors interact with estradiol and gonadotropins in the regulation of ovarian cancer cell growth and growth factor receptors. Oncol Res 5(8):325–337PubMedGoogle Scholar
  78. 78.
    Krywicki RF, Figueroa JA, Jackson JG, Kozelsky TW, Shimasaki S, Von Hoff DD, Yee D (1993) Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen. Eur J Cancer 29A(14):2015–2019PubMedCrossRefGoogle Scholar
  79. 79.
    Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O (2007) Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol 193(3):421–433. doi:10.1677/JOE-07-0087 PubMedCrossRefGoogle Scholar
  80. 80.
    Mukherjee K, Syed V, Ho SM (2005) Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells. Oncogene 24(27):4388–4400. doi:10.1038/sj.onc.1208623 PubMedCrossRefGoogle Scholar
  81. 81.
    Kang SK, Choi KC, Tai CJ, Auersperg N, Leung PC (2001) Estradiol regulates gonadotropin-releasing hormone (GnRH) and its receptor gene expression and antagonizes the growth inhibitory effects of GnRH in human ovarian surface epithelial and ovarian cancer cells. Endocrinology 142(2):580–588PubMedCrossRefGoogle Scholar
  82. 82.
    Treeck O, Haldar C, Ortmann O (2006) Antiestrogens modulate MT1 melatonin receptor expression in breast and ovarian cancer cell lines. Oncol Rep 15(1):231–235PubMedGoogle Scholar
  83. 83.
    Abu-Jawdeh GM, Jacobs TW, Niloff J, Cannistra SA (1996) Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol Oncol 60(2):301–307. doi:10.1006/gyno.1996.0043 PubMedCrossRefGoogle Scholar
  84. 84.
    Ho SM (2003) Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 1:73. doi:10.1186/1477-7827-1-73 PubMedCrossRefGoogle Scholar
  85. 85.
    Fauvet R, Dufournet Etienne C, Poncelet C, Bringuier AF, Feldmann G, Darai E (2006) Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3. Oncol Rep 15(4):743–748PubMedGoogle Scholar
  86. 86.
    Syed V, Mukherjee K, Godoy-Tundidor S, Ho SM (2007) Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression. J Cell Biochem 102(2):442–452. doi:10.1002/jcb.21304 PubMedCrossRefGoogle Scholar
  87. 87.
    Hua K, Feng W, Cao Q, Zhou X, Lu X, Feng Y (2008) Estrogen and progestin regulate metastasis through the PI3 K/AKT pathway in human ovarian cancer. Int J Oncol 33(5):959–967PubMedGoogle Scholar
  88. 88.
    Peluso JJ (2011) Progesterone signaling mediated through progesterone receptor membrane component-1 in ovarian cells with special emphasis on ovarian cancer. Steroids 76(9):903–909. doi:10.1016/j.steroids.2011.02.011 PubMedGoogle Scholar
  89. 89.
    Takahashi A, Kato K, Kuboyama A, Inoue T, Tanaka Y, Kuhara A, Kinoshita K, Takeda S, Wake N (2009) Induction of senescence by progesterone receptor-B activation in response to cAMP in ovarian cancer cells. Gynecol Oncol 113(2):270–276. doi:10.1016/j.ygyno.2008.12.032 PubMedCrossRefGoogle Scholar
  90. 90.
    Gabra H, Langdon SP, Watson JE, Hawkins RA, Cohen BB, Taylor L, Mackay J, Steel CM, Leonard RC, Smyth JF (1995) Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancer. Clin Cancer Res 1(9):945–953PubMedGoogle Scholar
  91. 91.
    Davis M, Hitchcock A, Foulkes WD, Campbell IG (1996) Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Cancer Res 56(4):741–744PubMedGoogle Scholar
  92. 92.
    Zhao D, Zhang F, Zhang W, He J, Zhao Y, Sun J (2013) Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 23(1):25–33. doi:10.1097/IGC.0b013e3182788466 PubMedCrossRefGoogle Scholar
  93. 93.
    Murdoch WJ, Van Kirk EA, Isaak DD, Shen Y (2008) Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts. Gynecol Oncol 110(2):251–255. doi:10.1016/j.ygyno.2008.03.021 PubMedCrossRefGoogle Scholar
  94. 94.
    Peluso JJ, Gawkowska A, Liu X, Shioda T, Pru JK (2009) Progesterone receptor membrane component-1 regulates the development and Cisplatin sensitivity of human ovarian tumors in athymic nude mice. Endocrinology 150(11):4846–4854. doi:10.1210/en.2009-0730 PubMedCrossRefGoogle Scholar
  95. 95.
    Romero-Sanchez M, Peiper SC, Evans B, Wang Z, Catasus L, Ribe A, Prat J, Giri JG (2008) Expression profile of heptahelical putative membrane progesterone receptors in epithelial ovarian tumors. Hum Pathol 39(7):1026–1033. doi:10.1016/j.humpath.2007.11.007 PubMedCrossRefGoogle Scholar
  96. 96.
    Peluso JJ (2006) Multiplicity of progesterone’s actions and receptors in the mammalian ovary. Biol Reprod 75(1):2–8. doi:10.1095/biolreprod.105.049924 PubMedCrossRefGoogle Scholar
  97. 97.
    Cardillo MR, Petrangeli E, Aliotta N, Salvatori L, Ravenna L, Chang C, Castagna G (1998) Androgen receptors in ovarian tumors: correlation with oestrogen and progesterone receptors in an immunohistochemical and semiquantitative image analysis study. J Exp Clin Cancer Res 17(2):231–237PubMedGoogle Scholar
  98. 98.
    Edmondson RJ, Monaghan JM, Davies BR (2002) The human ovarian surface epithelium is an androgen responsive tissue. Br J Cancer 86(6):879–885. doi:10.1038/sj.bjc.6600154 PubMedCrossRefGoogle Scholar
  99. 99.
    Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Dahl D, Brufsky A, Talcott J, Hennekens CH, Kantoff PW (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94(7):3320–3323PubMedCrossRefGoogle Scholar
  100. 100.
    Li AJ, Elmore RG, Pavelka JC, Karlan BY (2007) Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. Gynecol Oncol 107(3):420–423. doi:10.1016/j.ygyno.2007.07.059 PubMedCrossRefGoogle Scholar
  101. 101.
    Evangelou A, Jindal SK, Brown TJ, Letarte M (2000) Down-regulation of transforming growth factor beta receptors by androgen in ovarian cancer cells. Cancer Res 60(4):929–935PubMedGoogle Scholar
  102. 102.
    Sheach LA, Adeney EM, Kucukmetin A, Wilkinson SJ, Fisher AD, Elattar A, Robson CN, Edmondson RJ (2009) Androgen-related expression of G-proteins in ovarian cancer. Br J Cancer 101(3):498–503. doi:10.1038/sj.bjc.6605153 PubMedCrossRefGoogle Scholar
  103. 103.
    Ilekis JV, Connor JP, Prins GS, Ferrer K, Niederberger C, Scoccia B (1997) Expression of epidermal growth factor and androgen receptors in ovarian cancer. Gynecol Oncol 66(2):250–254. doi:10.1006/gyno.1997.4764 PubMedCrossRefGoogle Scholar
  104. 104.
    Fathalla MF (1971) Incessant ovulation—a factor in ovarian neoplasia? Lancet 2(7716):163PubMedCrossRefGoogle Scholar
  105. 105.
    Schildkraut JM, Bastos E, Berchuck A (1997) Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer. J Natl Cancer Inst 89(13):932–938PubMedCrossRefGoogle Scholar
  106. 106.
    Kuhn E, Kurman RJ, Shih IM (2012) Ovarian cancer is an imported disease: fact or fiction? Curr Obstet Gynecol Rep 1(1):1–9. doi:10.1007/s13669-011-0004-1 PubMedCrossRefGoogle Scholar
  107. 107.
    Kim J, Coffey DM, Creighton CJ, Yu Z, Hawkins SM, Matzuk MM (2012) High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci USA 109(10):3921–3926. doi:10.1073/pnas.1117135109 PubMedCrossRefGoogle Scholar
  108. 108.
    Przybycin CG, Kurman RJ, Ronnett BM, Shih Ie M, Vang R (2010) Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol 34(10):1407–1416. doi:10.1097/PAS.0b013e3181ef7b16 PubMedCrossRefGoogle Scholar
  109. 109.
    Kuhn E, Kurman RJ, Vang R, Sehdev AS, Han G, Soslow R, Wang TL, Shih Ie M (2012) TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma–evidence supporting the clonal relationship of the two lesions. J Pathol 226(3):421–426. doi:10.1002/path.3023 PubMedCrossRefGoogle Scholar
  110. 110.
    Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC Jr, Lu KH (2005) Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 11(17):6116–6126. doi:10.1158/1078-0432.CCR-04-2509 PubMedCrossRefGoogle Scholar
  111. 111.
    Murdoch WJ, Martinchick JF (2004) Oxidative damage to DNA of ovarian surface epithelial cells affected by ovulation: carcinogenic implication and chemoprevention. Exp Biol Med (Maywood) 229(6):546–552Google Scholar
  112. 112.
    Cramer DW, Welch WR (1983) Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. J Natl Cancer Inst 71(4):717–721PubMedGoogle Scholar
  113. 113.
    Biskind GR, Biskind MS (1948) Atrophy of ovaries transplanted to the spleen in unilaterally castrated rats; proliferative changes following subsequent removal of intact ovary. Science 108(2797):137–138. doi:10.1126/science.108.2797.137 PubMedCrossRefGoogle Scholar
  114. 114.
    Blaakaer J, Baeksted M, Micic S, Albrectsen P, Rygaard J, Bock J (1995) Gonadotropin-releasing hormone agonist suppression of ovarian tumorigenesis in mice of the Wx/Wv genotype. Biol Reprod 53(4):775–779PubMedCrossRefGoogle Scholar
  115. 115.
    Chakravarti S, Collins WP, Forecast JD, Newton JR, Oram DH, Studd JW (1976) Hormonal profiles after the menopause. Br Med J 2(6039):784–787PubMedCrossRefGoogle Scholar
  116. 116.
    Risch HA (1998) Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90(23):1774–1786PubMedCrossRefGoogle Scholar
  117. 117.
    Silva EG, Tornos C, Fritsche HA Jr, el-Naggar A, Gray K, Ordonez NG, Luna M, Gershenson D (1997) The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model. Mod Pathol 10(9):879–883PubMedGoogle Scholar
  118. 118.
    Nishizuka Y, Sakakura T, Tsujimura T, Matsumoto K (1973) Steroid biosynthesis in vitro by dysgenetic ovaries induced by neonatal thymectomy in mice. Endocrinology 93(4):786–792PubMedCrossRefGoogle Scholar
  119. 119.
    Helzlsouer KJ, Alberg AJ, Gordon GB, Longcope C, Bush TL, Hoffman SC, Comstock GW (1995) Serum gonadotropins and steroid hormones and the development of ovarian cancer. JAMA 274(24):1926–1930PubMedCrossRefGoogle Scholar
  120. 120.
    Wynder EL, Dodo H, Barber HR (1969) Epidemiology of cancer of the ovary. Cancer 23(2):352–370PubMedCrossRefGoogle Scholar
  121. 121.
    Sonnichsen AC, Lindlacher U, Richter WO, Schwandt P (1990) Obesity, body fat distribution and the incidence of breast, cervical, endometrial and ovarian carcinomas. Dtsch Med Wochenschr 115(50):1906–1910. doi:10.1055/s-2008-1065242 PubMedCrossRefGoogle Scholar
  122. 122.
    Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies (2012). PLoS Med 9(4):e1001200. doi:10.1371/journal.pmed.1001200
  123. 123.
    Olsen CM, Green AC, Nagle CM, Jordan SJ, Whiteman DC, Bain CJ, Webb PM (2008) Epithelial ovarian cancer: testing the ‘androgens hypothesis’. Endocr Relat Cancer 15(4):1061–1068. doi:10.1677/ERC-08-0075 PubMedCrossRefGoogle Scholar
  124. 124.
    Kotsopoulos J, Baer HJ, Tworoger SS (2010) Anthropometric measures and risk of epithelial ovarian cancer: results from the nurses’ health study. Obesity (Silver Spring) 18(8):1625–1631. doi:10.1038/oby.2009.461 CrossRefGoogle Scholar
  125. 125.
    Lahmann PH, Cust AE, Friedenreich CM, Schulz M, Lukanova A, Kaaks R, Lundin E, Tjonneland A, Halkjaer J, Severinsen MT, Overvad K, Fournier A, Chabbert-Buffet N, Clavel-Chapelon F, Dossus L, Pischon T, Boeing H, Trichopoulou A, Lagiou P, Naska A, Palli D, Grioni S, Mattiello A, Tumino R, Sacerdote C, Redondo ML, Jakszyn P, Sanchez MJ, Tormo MJ, Ardanaz E, Arriola L, Manjer J, Jirstrom K, Bueno-de-Mesquita HB, May AM, Peeters PH, Onland-Moret NC, Bingham S, Khaw KT, Allen NE, Spencer E, Rinaldi S, Slimani N, Chajes V, Michaud D, Norat T, Riboli E (2010) Anthropometric measures and epithelial ovarian cancer risk in the European prospective investigation into cancer and nutrition. Int J Cancer 126(10):2404–2415. doi:10.1002/ijc.24952 PubMedGoogle Scholar
  126. 126.
    Rinaldi S, Dossus L, Lukanova A, Peeters PH, Allen NE, Key T, Bingham S, Khaw KT, Trichopoulos D, Trichopoulou A, Oikonomou E, Pera G, Larranaga N, Martinez-Garcia C, Ardanaz E, Quiros JR, Tormo MJ, Tjonneland A, Olsen A, Overvad K, Chang-Claude J, Linseisen J, Schulz M, Boeing H, van Gils CH, Bueno-de-Mesquita BH, Pala V, Palli D, Panico S, Tumino R, Vineis P, Clavel-Chapelon F, Mesrine S, Boutron-Ruault MC, Lundin E, Agren A, Berglund G, Manjer J, Kumle M, Lund E, Slimani N, Saracci R, Riboli E, Kaaks R (2007) Endogenous androgens and risk of epithelial ovarian cancer: results from the European prospective investigation into cancer and nutrition (EPIC). Cancer Epidemiol Biomarkers Prev 16(1):23–29. doi:10.1158/1055-9965.EPI-06-0755 PubMedCrossRefGoogle Scholar
  127. 127.
    Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN, Nomura AM, Terada KY, Carney ME, Sobin LH (2003) Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol 158(7):629–638PubMedCrossRefGoogle Scholar
  128. 128.
    Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, Lund E, Fournier A, Overvad K, Hansen L, Tjonneland A, Fedirko V, Rinaldi S, Romieu I, Clavel-Chapelon F, Engel P, Kaaks R, Schutze M, Steffen A, Bamia C, Trichopoulou A, Zylis D, Masala G, Pala V, Galasso R, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, van Duijnhoven FJ, Braem MG, Onland-Moret NC, Gram IT, Rodriguez L, Travier N, Sanchez MJ, Huerta JM, Ardanaz E, Larranaga N, Jirstrom K, Manjer J, Idahl A, Ohlson N, Khaw KT, Wareham N, Mouw T, Norat T, Riboli E (2011) Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer 105(9):1436–1442. doi:10.1038/bjc.2011.371 PubMedCrossRefGoogle Scholar
  129. 129.
    Gong TT, Wu QJ, Vogtmann E, Lin B, Wang YL (2012) Age at menarche and risk of ovarian cancer: A meta-analysis of epidemiological studies. Int J Cancer. doi:10.1002/ijc.27952
  130. 130.
    Soegaard M, Jensen A, Hogdall E, Christensen L, Hogdall C, Blaakaer J, Kjaer SK (2007) Different risk factor profiles for mucinous and nonmucinous ovarian cancer: results from the Danish MALOVA study. Cancer Epidemiol Biomarkers Prev 16(6):1160–1166. doi:10.1158/1055-9965.EPI-07-0089 PubMedCrossRefGoogle Scholar
  131. 131.
    Braem MG, Onland-Moret NC, van den Brandt PA, Goldbohm RA, Peeters PH, Kruitwagen RF, Schouten LJ (2010) Reproductive and hormonal factors in association with ovarian cancer in the Netherlands cohort study. Am J Epidemiol 172(10):1181–1189. doi:10.1093/aje/kwq264 PubMedCrossRefGoogle Scholar
  132. 132.
    Pelucchi C, Galeone C, Talamini R, Bosetti C, Montella M, Negri E, Franceschi S, LaVecchia C (2007) Lifetime ovulatory cycles and ovarian cancer risk in 2 Italian case-control studies. Am J Obstet Gynecol 196(1):83 e81–e87. doi:10.1016/j.ajog.2006.06.088 CrossRefGoogle Scholar
  133. 133.
    Chiaffarino F, Pelucchi C, Parazzini F, Negri E, Franceschi S, Talamini R, Conti E, Montella M, La Vecchia C (2001) Reproductive and hormonal factors and ovarian cancer. Ann Oncol 12(3):337–341PubMedCrossRefGoogle Scholar
  134. 134.
    Tavani A, Negri E, Franceschi S, Parazzini F, La Vecchia C (1993) Risk factors for epithelial ovarian cancer in women under age 45. Eur J Cancer 29A(9):1297–1301PubMedCrossRefGoogle Scholar
  135. 135.
    Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Persson IR (2002) Risk factors for invasive epithelial ovarian cancer: results from a Swedish case-control study. Am J Epidemiol 156(4):363–373PubMedCrossRefGoogle Scholar
  136. 136.
    Chiaffarino F, Pelucchi C, Negri E, Parazzini F, Franceschi S, Talamini R, Montella M, Ramazzotti V, La Vecchia C (2005) Breastfeeding and the risk of epithelial ovarian cancer in an Italian population. Gynecol Oncol 98(2):304–308. doi:10.1016/j.ygyno.2005.05.006 PubMedCrossRefGoogle Scholar
  137. 137.
    Booth M, Beral V, Smith P (1989) Risk factors for ovarian cancer: a case-control study. Br J Cancer 60(4):592–598PubMedCrossRefGoogle Scholar
  138. 138.
    Jordan SJ, Cushing-Haugen KL, Wicklund KG, Doherty JA, Rossing MA (2012) Breast-feeding and risk of epithelial ovarian cancer. Cancer Causes Control 23(6):919–927. doi:10.1007/s10552-012-9963-4 PubMedCrossRefGoogle Scholar
  139. 139.
    Titus-Ernstoff L, Rees JR, Terry KL, Cramer DW (2010) Breast-feeding the last born child and risk of ovarian cancer. Cancer Causes Control 21(2):201–207. doi:10.1007/s10552-009-9450-8 PubMedCrossRefGoogle Scholar
  140. 140.
    Nagle CM, Olsen CM, Webb PM, Jordan SJ, Whiteman DC, Green AC (2008) Endometrioid and clear cell ovarian cancers: a comparative analysis of risk factors. Eur J Cancer 44(16):2477–2484. doi:10.1016/j.ejca.2008.07.009 PubMedCrossRefGoogle Scholar
  141. 141.
    Danforth KN, Tworoger SS, Hecht JL, Rosner BA, Colditz GA, Hankinson SE (2007) Breastfeeding and risk of ovarian cancer in two prospective cohorts. Cancer Causes Control 18(5):517–523. doi:10.1007/s10552-007-0130-2 PubMedCrossRefGoogle Scholar
  142. 142.
    Siskind V, Green A, Bain C, Purdie D (1997) Breastfeeding, menopause, and epithelial ovarian cancer. Epidemiology 8(2):188–191PubMedCrossRefGoogle Scholar
  143. 143.
    Rosenblatt KA, Thomas DB (1993) Lactation and the risk of epithelial ovarian cancer. The WHO collaborative study of neoplasia and steroid contraceptives. Int J Epidemiol 22(2):192–197PubMedCrossRefGoogle Scholar
  144. 144.
    Risch HA, Weiss NS, Lyon JL, Daling JR, Liff JM (1983) Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 117(2):128–139PubMedGoogle Scholar
  145. 145.
    Whittemore AS, Harris R, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative ovarian cancer group. Am J Epidemiol 136(10):1184–1203PubMedGoogle Scholar
  146. 146.
    Jordan SJ, Siskind V, A CG, Whiteman DC, Webb PM (2010) Breastfeeding and risk of epithelial ovarian cancer. Cancer Causes Control 21(1):109–116. doi:10.1007/s10552-009-9440-x PubMedCrossRefGoogle Scholar
  147. 147.
    Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER (2001) Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 84(5):714–721. doi:10.1054/bjoc.2000.1596 PubMedCrossRefGoogle Scholar
  148. 148.
    Mills PK, Riordan DG, Cress RD (2004) Epithelial ovarian cancer risk by invasiveness and cell type in the central valley of California. Gynecol Oncol 95(1):215–225. doi:10.1016/j.ygyno.2004.07.012 PubMedCrossRefGoogle Scholar
  149. 149.
    Gates MA, Rosner BA, Hecht JL, Tworoger SS (2010) Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 171(1):45–53. doi:10.1093/aje/kwp314 PubMedCrossRefGoogle Scholar
  150. 150.
    Purdie DM, Siskind V, Bain CJ, Webb PM, Green AC (2001) Reproduction-related risk factors for mucinous and nonmucinous epithelial ovarian cancer. Am J Epidemiol 153(9):860–864PubMedCrossRefGoogle Scholar
  151. 151.
    McNeilly AS (2001) Lactational control of reproduction. Reprod Fertil Dev 13(7–8):583–590PubMedCrossRefGoogle Scholar
  152. 152.
    Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I, Ekbom A, Janson PO (1994) Parity, age at first childbirth, and risk of ovarian cancer. Lancet 344(8932):1250–1254. pii: S0140-6736(94)90749-8PubMedCrossRefGoogle Scholar
  153. 153.
    Risch HA, Marrett LD, Howe GR (1994) Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 140(7):585–597PubMedGoogle Scholar
  154. 154.
    Liu Q, Lambe M, Baik I, Cnattingius S, Riman T, Ekbom A, Adami HO, Hsieh CC (2006) A prospective study of the transient decrease in ovarian cancer risk following childbirth. Cancer Epidemiol Biomarkers Prev 15(12):2508–2513. doi:10.1158/1055-9965.EPI-06-0242 PubMedCrossRefGoogle Scholar
  155. 155.
    Hinkula M, Pukkala E, Kyyronen P, Kauppila A (2006) Incidence of ovarian cancer of grand multiparous women–a population-based study in Finland. Gynecol Oncol 103(1):207–211. doi:10.1016/j.ygyno.2006.02.025 PubMedCrossRefGoogle Scholar
  156. 156.
    Whiteman DC, Murphy MF, Cook LS, Cramer DW, Hartge P, Marchbanks PA, Nasca PC, Ness RB, Purdie DM, Risch HA (2000) Multiple births and risk of epithelial ovarian cancer. J Natl Cancer Inst 92(14):1172–1177PubMedCrossRefGoogle Scholar
  157. 157.
    Albrektsen G, Heuch I, Kvale G (1996) Reproductive factors and incidence of epithelial ovarian cancer: a Norwegian prospective study. Cancer Causes Control 7(4):421–427PubMedCrossRefGoogle Scholar
  158. 158.
    Chen MT, Cook LS, Daling JR, Weiss NS (1996) Incomplete pregnancies and risk of ovarian cancer (Washington, United States). Cancer Causes Control 7(4):415–420PubMedCrossRefGoogle Scholar
  159. 159.
    Purdie D, Green A, Bain C, Siskind V, Ward B, Hacker N, Quinn M, Wright G, Russell P, Susil B (1995) Reproductive and other factors and risk of epithelial ovarian cancer: an Australian case-control study. Survey of women’s health study group. Int J Cancer 62(6):678–684PubMedCrossRefGoogle Scholar
  160. 160.
    Hankinson SE, Colditz GA, Hunter DJ, Willett WC, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE (1995) A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 76(2):284–290PubMedCrossRefGoogle Scholar
  161. 161.
    Bernal A, Mendez-Moran L, Fajardo-Gutierrez A, Gonzalez-Lira G, Escudero P, Ortiz H (1995) Univariate and multivariate analysis of risk factors for ovarian cancer: case-control study. Mexico City. Arch Med Res 26(3):245–249Google Scholar
  162. 162.
    Lund E (1992) Mortality from ovarian cancer among women with many children. Int J Epidemiol 21(5):872–876PubMedCrossRefGoogle Scholar
  163. 163.
    Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Persson IR (2001) Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol 83(3):575–585. doi:10.1006/gyno.2001.6451 PubMedCrossRefGoogle Scholar
  164. 164.
    Harlow BL, Weiss NS, Roth GJ, Chu J, Daling JR (1988) Case-control study of borderline ovarian tumors: reproductive history and exposure to exogenous female hormones. Cancer Res 48(20):5849–5852PubMedGoogle Scholar
  165. 165.
    Harris R, Whittemore AS, Itnyre J (1992) Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Collaborative ovarian cancer group. Am J Epidemiol 136(10):1204–1211PubMedGoogle Scholar
  166. 166.
    Parazzini F, Restelli C, La Vecchia C, Negri E, Chiari S, Maggi R, Mangioni C (1991) Risk factors for epithelial ovarian tumours of borderline malignancy. Int J Epidemiol 20(4):871–877PubMedCrossRefGoogle Scholar
  167. 167.
    Merrill RM, Fugal S, Novilla LB, Raphael MC (2005) Cancer risk associated with early and late maternal age at first birth. Gynecol Oncol 96(3):583–593. doi:10.1016/j.ygyno.2004.11.038 PubMedCrossRefGoogle Scholar
  168. 168.
    Risch HA, Marrett LD, Jain M, Howe GR (1996) Differences in risk factors for epithelial ovarian cancer by histologic type. Results of a case-control study. Am J Epidemiol 144(4):363–372PubMedCrossRefGoogle Scholar
  169. 169.
    Kvale G, Heuch I, Nilssen S, Beral V (1988) Reproductive factors and risk of ovarian cancer: a prospective study. Int J Cancer 42(2):246–251PubMedCrossRefGoogle Scholar
  170. 170.
    Kurian AW, Balise RR, McGuire V, Whittemore AS (2005) Histologic types of epithelial ovarian cancer: have they different risk factors? Gynecol Oncol 96(2):520–530. doi:10.1016/j.ygyno.2004.10.037 PubMedCrossRefGoogle Scholar
  171. 171.
    Jordan SJ, Green AC, Nagle CM, Olsen CM, Whiteman DC, Webb PM (2009) Beyond parity: association of ovarian cancer with length of gestation and offspring characteristics. Am J Epidemiol 170(5):607–614. doi:10.1093/aje/kwp185 PubMedCrossRefGoogle Scholar
  172. 172.
    Brinton LA, Melton LJ 3rd, Malkasian GD Jr, Bond A, Hoover R (1989) Cancer risk after evaluation for infertility. Am J Epidemiol 129(4):712–722PubMedGoogle Scholar
  173. 173.
    Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, Oelsner G, Freedman L, Mashiach S, Lunenfeld B (1998) Cancer incidence in a cohort of infertile women. Am J Epidemiol 147(11):1038–1042PubMedCrossRefGoogle Scholar
  174. 174.
    Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A (1999) Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril 71(5):853–859. pii: S0015-0282(99)00085-0PubMedCrossRefGoogle Scholar
  175. 175.
    Venn A, Watson L, Bruinsma F, Giles G, Healy D (1999) Risk of cancer after use of fertility drugs with in vitro fertilisation. Lancet 354(9190):1586–1590. doi:10.1016/S0140-6736(99)05203-4 PubMedCrossRefGoogle Scholar
  176. 176.
    Ness RB, Cramer DW, Goodman MT, Kjaer SK, Mallin K, Mosgaard BJ, Purdie DM, Risch HA, Vergona R, Wu AH (2002) Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am J Epidemiol 155(3):217–224PubMedCrossRefGoogle Scholar
  177. 177.
    Rodriguez C, Tatham LM, Calle EE, Thun MJ, Jacobs EJ, Heath CW Jr (1998) Infertility and risk of fatal ovarian cancer in a prospective cohort of US women. Cancer Causes Control 9(6):645–651PubMedCrossRefGoogle Scholar
  178. 178.
    Rossing MA, Tang MT, Flagg EW, Weiss LK, Wicklund KG (2004) A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol 160(11):1070–1078. doi:10.1093/aje/kwh315 PubMedCrossRefGoogle Scholar
  179. 179.
    Jensen A, Sharif H, Olsen JH, Kjaer SK (2008) Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. Am J Epidemiol 168(1):49–57. doi:10.1093/aje/kwn094 PubMedCrossRefGoogle Scholar
  180. 180.
    Tworoger SS, Fairfield KM, Colditz GA, Rosner BA, Hankinson SE (2007) Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol 166(8):894–901. doi:10.1093/aje/kwm157 PubMedCrossRefGoogle Scholar
  181. 181.
    Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL (2004) Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol 103(6):1194–1203. doi:10.1097/01.AOG.0000128139.92313.74 PubMedCrossRefGoogle Scholar
  182. 182.
    Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, Westhoff CL (2004) Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 82(2):405–414. doi:10.1016/j.fertnstert.2004.02.109 PubMedCrossRefGoogle Scholar
  183. 183.
    Pearce CL, Templeman C, Rossing MA, Lee A, Near AM, Webb PM, Nagle CM, Doherty JA, Cushing-Haugen KL, Wicklund KG, Chang-Claude J, Hein R, Lurie G, Wilkens LR, Carney ME, Goodman MT, Moysich K, Kjaer SK, Hogdall E, Jensen A, Goode EL, Fridley BL, Larson MC, Schildkraut JM, Palmieri RT, Cramer DW, Terry KL, Vitonis AF, Titus LJ, Ziogas A, Brewster W, Anton-Culver H, Gentry-Maharaj A, Ramus SJ, Anderson AR, Brueggmann D, Fasching PA, Gayther SA, Huntsman DG, Menon U, Ness RB, Pike MC, Risch H, Wu AH, Berchuck A (2012) Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol 13(4):385–394. doi:10.1016/S1470-2045(11)70404-1 PubMedCrossRefGoogle Scholar
  184. 184.
    Schildkraut JM, Schwingl PJ, Bastos E, Evanoff A, Hughes C (1996) Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 88(4 Pt 1):554–559PubMedCrossRefGoogle Scholar
  185. 185.
    Chittenden BG, Fullerton G, Maheshwari A, Bhattacharya S (2009) Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online 19(3):398–405PubMedCrossRefGoogle Scholar
  186. 186.
    Rebar R, Judd HL, Yen SS, Rakoff J, Vandenberg G, Naftolin F (1976) Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome. J Clin Invest 57(5):1320–1329. doi:10.1172/JCI108400 PubMedCrossRefGoogle Scholar
  187. 187.
    Baird DT, Corker CS, Davidson DW, Hunter WM, Michie EA, Van Look PF (1977) Pituitary-ovarian relationships in polycystic ovary syndrome. J Clin Endocrinol Metab 45(4):798–801PubMedCrossRefGoogle Scholar
  188. 188.
    Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ (2007) Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ 335(7621):651. doi:10.1136/bmj.39289.649410.55 PubMedCrossRefGoogle Scholar
  189. 189.
    Ness RB, Dodge RC, Edwards RP, Baker JA, Moysich KB (2011) Contraception methods, beyond oral contraceptives and tubal ligation, and risk of ovarian cancer. Ann Epidemiol 21(3):188–196. doi:10.1016/j.annepidem.2010.10.002 PubMedCrossRefGoogle Scholar
  190. 190.
    Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, Zikan M, Dusek L (2010) Hormonal contraception and risk of cancer. Hum Reprod Update 16(6):631–650. doi:10.1093/humupd/dmq022 PubMedCrossRefGoogle Scholar
  191. 191.
    Grimbizis GF, Tarlatzis BC (2010) The use of hormonal contraception and its protective role against endometrial and ovarian cancer. Best Pract Res Clin Obstet Gynaecol 24(1):29–38. doi:10.1016/j.bpobgyn.2009.08.010 PubMedCrossRefGoogle Scholar
  192. 192.
    Lurie G, Thompson P, McDuffie KE, Carney ME, Terada KY, Goodman MT (2007) Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol 109(3):597–607. doi:10.1097/01.AOG.0000255664.48970.e6 PubMedCrossRefGoogle Scholar
  193. 193.
    Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Lewis JL Jr, Strom BL, Harlap S, Shapiro S (1994) A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139(7):654–661PubMedGoogle Scholar
  194. 194.
    Walker GR, Schlesselman JJ, Ness RB (2002) Family history of cancer, oral contraceptive use, and ovarian cancer risk. Am J Obstet Gynecol 186(1):8–14. pii: S0002937802860628PubMedCrossRefGoogle Scholar
  195. 195.
    Ness RB, Grisso JA, Vergona R, Klapper J, Morgan M, Wheeler JE (2001) Oral contraceptives, other methods of contraception, and risk reduction for ovarian cancer. Epidemiology 12(3):307–312PubMedCrossRefGoogle Scholar
  196. 196.
    Beral V, Hermon C, Kay C, Hannaford P, Darby S, Reeves G (1999) Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of General Practitioners’ oral contraception study. BMJ 318(7176):96–100PubMedCrossRefGoogle Scholar
  197. 197.
    Gwinn ML, Lee NC, Rhodes PH, Layde PM, Rubin GL (1990) Pregnancy, breast feeding, and oral contraceptives and the risk of epithelial ovarian cancer. J Clin Epidemiol 43(6):559–568. pii: 0895-4356(90)90160-QPubMedCrossRefGoogle Scholar
  198. 198.
    Rosenberg L, Shapiro S, Slone D, Kaufman DW, Helmrich SP, Miettinen OS, Stolley PD, Rosenshein NB, Schottenfeld D, Engle RL Jr (1982) Epithelial ovarian cancer and combination oral contraceptives. JAMA 247(23):3210–3212PubMedCrossRefGoogle Scholar
  199. 199.
    Beral V, Doll R, Hermon C, Peto R, Reeves G (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371(9609):303–314. doi:10.1016/S0140-6736(08)60167-1 PubMedCrossRefGoogle Scholar
  200. 200.
    Parazzini F, Chiaffarino F, Negri E, Surace M, Benzi G, Franceschi S, Fedele L, La Vecchia C (2004) Risk factors for different histological types of ovarian cancer. Int J Gynecol Cancer 14(3):431–436. doi:10.1111/j.1048-891x.2004.14302.x PubMedCrossRefGoogle Scholar
  201. 201.
    Wittenberg J, Cook LS, Rossing MA, Weiss NS (1999) Reproductive risk factors for mucinous and non-mucinous epithelial ovarian cancer. Epidemiology 10(6):761–763PubMedCrossRefGoogle Scholar
  202. 202.
    Siskind V, Green A, Bain C, Purdie D (2000) Beyond ovulation: oral contraceptives and epithelial ovarian cancer. Epidemiology 11(2):106–110PubMedCrossRefGoogle Scholar
  203. 203.
    Riman T, Nilsson S, Persson IR (2004) Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 83(9):783–795. doi:10.1111/j.0001-6349.2004.00550.x PubMedGoogle Scholar
  204. 204.
    Bosetti C, Negri E, Franceschi S, Trichopoulos D, Beral V, La Vecchia C (2001) Relationship between postmenopausal hormone replacement therapy and ovarian cancer. JAMA 285 (24):3089; author reply 3090. pii: jlt0627-2Google Scholar
  205. 205.
    Garg PP, Kerlikowske K, Subak L, Grady D (1998) Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet Gynecol 92(3):472–479. pii: S0029-7844(98)00139-2PubMedCrossRefGoogle Scholar
  206. 206.
    Lacey JV Jr, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P, Schatzkin A, Schairer C (2002) Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 288(3):334–341. pii: joc20074PubMedCrossRefGoogle Scholar
  207. 207.
    Negri E, Tzonou A, Beral V, Lagiou P, Trichopoulos D, Parazzini F, Franceschi S, Booth M, La Vecchia C (1999) Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int J Cancer 80(6):848–851. doi:10.1002/(SICI)1097-0215(19990315)80:6<848:AID-IJC8>3.0.CO;2-E PubMedCrossRefGoogle Scholar
  208. 208.
    Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, Weiderpass E, Persson IR (2002) Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 94(7):497–504PubMedCrossRefGoogle Scholar
  209. 209.
    Ortmann O, Doren M, Windler E (2011) Hormone therapy in perimenopause and postmenopause (HT). Interdisciplinary S3 Guideline, Association of the Scientific Medical Societies in Germany AWMF 015/062-short version. Arch Gynecol Obstet 284(2):343–355. doi:10.1007/s00404-011-1878-x PubMedCrossRefGoogle Scholar
  210. 210.
    Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck A, Danforth KN, Park Y, Brinton LA (2012) Ovarian cancer and menopausal hormone therapy in the NIH-AARP diet and health study. Br J Cancer 107(7):1181–1187. doi:10.1038/bjc.2012.397 PubMedCrossRefGoogle Scholar
  211. 211.
    Glud E, Kjaer SK, Thomsen BL, Hogdall C, Christensen L, Hogdall E, Bock JE, Blaakaer J (2004) Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch Intern Med 164(20):2253–2259. doi:10.1001/archinte.164.20.2253 PubMedCrossRefGoogle Scholar
  212. 212.
    Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SA, Pettinger M, Liu J, McNeeley SG, Lopez AM (2003) Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA 290(13):1739–1748. doi:10.1001/jama.290.13.1739 PubMedCrossRefGoogle Scholar
  213. 213.
    Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ (2001) Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285(11):1460–1465. pii: joc01947PubMedCrossRefGoogle Scholar
  214. 214.
    Greiser CM, Greiser EM, Doren M (2007) Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update 13(5):453–463. doi:10.1093/humupd/dmm012 PubMedCrossRefGoogle Scholar
  215. 215.
    Beral V, Bull D, Green J, Reeves G (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369(9574):1703–1710. doi:10.1016/S0140-6736(07)60534-0 PubMedCrossRefGoogle Scholar
  216. 216.
    Rossing MA, Cushing-Haugen KL, Wicklund KG, Doherty JA, Weiss NS (2007) Menopausal hormone therapy and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 16(12):2548–2556. doi:10.1158/1055-9965.EPI-07-0550 PubMedCrossRefGoogle Scholar
  217. 217.
    Hildebrand JS, Gapstur SM, Feigelson HS, Teras LR, Thun MJ, Patel AV (2010) Postmenopausal hormone use and incident ovarian cancer: associations differ by regimen. Int J Cancer 127(12):2928–2935. doi:10.1002/ijc.25515 PubMedCrossRefGoogle Scholar
  218. 218.
    Lacey JV Jr, Brinton LA, Leitzmann MF, Mouw T, Hollenbeck A, Schatzkin A, Hartge P (2006) Menopausal hormone therapy and ovarian cancer risk in the National Institutes of Health-AARP Diet and Health Study Cohort. J Natl Cancer Inst 98(19):1397–1405. doi:10.1093/jnci/djj375 PubMedCrossRefGoogle Scholar
  219. 219.
    Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L, Wang B (2008) Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol Oncol 108(3):641–651. doi:10.1016/j.ygyno.2007.12.003 PubMedCrossRefGoogle Scholar
  220. 220.
    Pearce CL, Chung K, Pike MC, Wu AH (2009) Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin. Cancer 115(3):531–539. doi:10.1002/cncr.23956 PubMedCrossRefGoogle Scholar
  221. 221.
    Tsilidis KK, Allen NE, Key TJ, Dossus L, Kaaks R, Bakken K, Lund E, Fournier A, Dahm CC, Overvad K, Hansen L, Tjonneland A, Rinaldi S, Romieu I, Boutron-Ruault MC, Clavel-Chapelon F, Lukanova A, Boeing H, Schutze M, Benetou V, Palli D, Berrino F, Galasso R, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, van Duijnhoven FJ, Braem MG, Onland-Moret NC, Gram IT, Rodriguez L, Duell EJ, Sanchez MJ, Huerta JM, Ardanaz E, Amiano P, Khaw KT, Wareham N, Riboli E (2011) Menopausal hormone therapy and risk of ovarian cancer in the European prospective investigation into cancer and nutrition. Cancer Causes Control 22(8):1075–1084. doi:10.1007/s10552-011-9782-z PubMedCrossRefGoogle Scholar
  222. 222.
    Morch LS, Lokkegaard E, Andreasen AH, Kruger-Kjaer S, Lidegaard O (2009) Hormone therapy and ovarian cancer. JAMA 302(3):298–305. doi:10.1001/jama.2009.1052 PubMedCrossRefGoogle Scholar
  223. 223.
    Purdie DM, Bain CJ, Siskind V, Russell P, Hacker NF, Ward BG, Quinn MA, Green AC (1999) Hormone replacement therapy and risk of epithelial ovarian cancer. Br J Cancer 81(3):559–563. doi:10.1038/sj.bjc.6690731 PubMedCrossRefGoogle Scholar
  224. 224.
    Risch HA (1996) Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 63(2):254–257. doi:10.1006/gyno.1996.0315 PubMedCrossRefGoogle Scholar
  225. 225.
    Yang HP, Trabert B, Murphy MA, Sherman ME, Sampson JN, Brinton LA, Hartge P, Hollenbeck A, Park Y, Wentzensen N (2012) Ovarian cancer risk factors by histologic subtypes in the NIH-AARP Diet and Health Study. Int J Cancer 131(4):938–948. doi:10.1002/ijc.26469 PubMedCrossRefGoogle Scholar
  226. 226.
    Matei MC, Caruntu ID, Negura L, Petrariu FD, Ifrim S, Acatrinei L, Sulugiuc A, Azoicai D (2010) The assessment of relations between main histologic type of ovarian cancer and some risk and prognostic factors. Rev Med Chir Soc Med Nat Iasi 114(4):1135–1141PubMedGoogle Scholar
  227. 227.
    Mills PK, Riordan DG, Cress RD, Goldsmith DF (2005) Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk. Cancer Detect Prev 29(2):124–132. doi:10.1016/j.cdp.2004.11.002 PubMedCrossRefGoogle Scholar
  228. 228.
    Morch LS, Lokkegaard E, Andreasen AH, Kjaer SK, Lidegaard O (2012) Hormone therapy and ovarian borderline tumors: a national cohort study. Cancer Causes Control 23(1):113–120. doi:10.1007/s10552-011-9860-2 PubMedCrossRefGoogle Scholar
  229. 229.
    Martinez F, Manubens M, Carreras O, Tur R, Barri PN (1993) Ovarian function during hormonal replacement therapy in perimenopausal women. Adv Contracept 9(1):71–74PubMedCrossRefGoogle Scholar
  230. 230.
    Gebbie AE, Glasier A, Sweeting V (1995) Incidence of ovulation in perimenopausal women before and during hormone replacement therapy. Contraception 52(4):221–222. pii: 001078249500184CPubMedCrossRefGoogle Scholar
  231. 231.
    Waaseth M, Bakken K, Dumeaux V, Olsen KS, Rylander C, Figenschau Y, Lund E (2008) Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer postgenome cohort—a cross-sectional analysis. BMC Womens Health 8:1. doi:10.1186/1472-6874-8-1 PubMedCrossRefGoogle Scholar
  232. 232.
    Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG (1994) Ovarian tumors in a cohort of infertile women. N Engl J Med 331(12):771–776. doi:10.1056/NEJM199409223311204 PubMedCrossRefGoogle Scholar
  233. 233.
    Sanner K, Conner P, Bergfeldt K, Dickman P, Sundfeldt K, Bergh T, Hagenfeldt K, Janson PO, Nilsson S, Persson I (2009) Ovarian epithelial neoplasia after hormonal infertility treatment: long-term follow-up of a historical cohort in Sweden. Fertil Steril 91(4):1152–1158. doi:10.1016/j.fertnstert.2008.01.073 PubMedCrossRefGoogle Scholar
  234. 234.
    Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG (1996) Human menopausal gonadotropin and the risk of epithelial ovarian cancer. Fertil Steril 65(1):13–18PubMedGoogle Scholar
  235. 235.
    Parazzini F, Negri E, La Vecchia C, Moroni S, Polatti A, Chiaffarino F, Surace M, Ricci E (1998) Treatment for fertility and risk of ovarian tumors of borderline malignancy. Gynecol Oncol 68(3):226–228. doi:10.1006/gyno.1997.4928 PubMedCrossRefGoogle Scholar
  236. 236.
    Goldberg GL, Runowicz CD (1992) Ovarian carcinoma of low malignant potential, infertility, and induction of ovulation–is there a link? Am J Obstet Gynecol 166(3):853–854. pii: 0002-9378(92)91348-EPubMedCrossRefGoogle Scholar
  237. 237.
    van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AM, Lambalk CB, Kortman M, Laven JS, Jansen CA, Helmerhorst FM, Cohlen BJ, Willemsen WN, Smeenk JM, Simons AH, van der Veen F, Evers JL, van Dop PA, Macklon NS, Burger CW (2011) Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod 26(12):3456–3465. doi:10.1093/humrep/der322 PubMedCrossRefGoogle Scholar
  238. 238.
    Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN (1998) Ovarian stimulation and borderline ovarian tumors: a case-control study. Fertil Steril 70(6):1049–1055. pii: S0015028298003379PubMedCrossRefGoogle Scholar
  239. 239.
    Parazzini F, Negri E, La Vecchia C, Moroni S, Franceschi S, Crosignani PG (1997) Treatment for infertility and risk of invasive epithelial ovarian cancer. Hum Reprod 12(10):2159–2161PubMedCrossRefGoogle Scholar
  240. 240.
    Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Andersen AN (1997) Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril 67(6):1005–1012. pii: S0015028297814318PubMedCrossRefGoogle Scholar
  241. 241.
    Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL (2002) Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 17(8):2209–2213PubMedCrossRefGoogle Scholar
  242. 242.
    Kurta ML, Moysich KB, Weissfeld JL, Youk AO, Bunker CH, Edwards RP, Modugno F, Ness RB, Diergaarde B (2012) Use of fertility drugs and risk of ovarian cancer: results from a U.S.-based case-control study. Cancer Epidemiol Biomarkers Prev 21(8):1282–1292. doi:10.1158/1055-9965.EPI-12-0426 PubMedCrossRefGoogle Scholar
  243. 243.
    Liat LG, Jaron R, Liraz O, Tzvia B, Shlomo M, Bruno L (2012) Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow-up. Gynecol Endocrinol 28(10):809–814. doi:10.3109/09513590.2012.671391 PubMedCrossRefGoogle Scholar
  244. 244.
    Cusido M, Fabregas R, Pere BS, Escayola C, Barri PN (2007) Ovulation induction treatment and risk of borderline ovarian tumors. Gynecol Endocrinol 23(7):373–376. doi:10.1080/09513590701350341 PubMedCrossRefGoogle Scholar
  245. 245.
    Jensen A, Jensen A, Sharif H, Sharif H, Frederiksen K, Frederiksen K (2009) Use of fertility drugs and risk of ovarian cancer: Danish Population Based Cohort Study. BMJ British MedicalGoogle Scholar
  246. 246.
    Kashyap S, Moher D, Fung MF, Rosenwaks Z (2004) Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol 103(4):785–794. doi:10.1097/01.AOG.0000119226.39514.1d PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • Susanne Schüler
    • 1
  • Marvin Ponnath
    • 1
  • Jörg Engel
    • 1
  • Olaf Ortmann
    • 1
  1. 1.Department of Obstetrics and GynecologyUniversity of RegensburgRegensburgGermany

Personalised recommendations